- Home
- GRPN vs CDXC Comparison
GRPN vs CDXC Comparison
Compare GRPN & CDXC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GRPN
- CDXC
- Stock Information
- Founded
- GRPN 2008
- CDXC 1999
- Country
- GRPN United States
- CDXC United States
- Employees
- GRPN N/A
- CDXC N/A
- Industry
- GRPN Advertising
- CDXC Medicinal Chemicals and Botanical Products
- Sector
- GRPN Consumer Discretionary
- CDXC Health Care
- Exchange
- GRPN Nasdaq
- CDXC Nasdaq
- Market Cap
- GRPN 473.0M
- CDXC 415.5M
- IPO Year
- GRPN 2011
- CDXC N/A
- Fundamental
- Price
- GRPN $10.79
- CDXC $6.09
- Analyst Decision
- GRPN Hold
- CDXC Strong Buy
- Analyst Count
- GRPN 3
- CDXC 2
- Target Price
- GRPN $17.00
- CDXC $8.00
- AVG Volume (30 Days)
- GRPN 987.1K
- CDXC 431.2K
- Earning Date
- GRPN 03-14-2025
- CDXC 03-05-2025
- Dividend Yield
- GRPN N/A
- CDXC N/A
- EPS Growth
- GRPN N/A
- CDXC N/A
- EPS
- GRPN 0.52
- CDXC 0.02
- Revenue
- GRPN $499,894,000.00
- CDXC $91,668,000.00
- Revenue This Year
- GRPN N/A
- CDXC $18.64
- Revenue Next Year
- GRPN $0.32
- CDXC $20.72
- P/E Ratio
- GRPN $20.78
- CDXC $311.55
- Revenue Growth
- GRPN N/A
- CDXC 9.95
- 52 Week Low
- GRPN $7.75
- CDXC $1.36
- 52 Week High
- GRPN $19.56
- CDXC $7.97
- Technical
- Relative Strength Index (RSI)
- GRPN 43.16
- CDXC 57.85
- Support Level
- GRPN $10.53
- CDXC $5.17
- Resistance Level
- GRPN $11.26
- CDXC $5.52
- Average True Range (ATR)
- GRPN 0.65
- CDXC 0.26
- MACD
- GRPN -0.21
- CDXC 0.10
- Stochastic Oscillator
- GRPN 11.71
- CDXC 86.92
About GRPN Groupon Inc.
Groupon Inc acts as the middleman between consumers and merchants, offering a variety of products and services at discounts via its online store. It offers consumers daily deals from local merchants. The company's operations are organized into two segments: North America and International. The company generates the majority of its revenue from North America. The company generates revenue from transactions during which the company generates commissions by selling goods or services on behalf of third-party merchants. Revenue also includes commissions the company earn when customers make purchases with retailers using digital coupons accessed through its digital properties.
About CDXC ChromaDex Corporation
ChromaDex Corp is a bioscience company dedicated to healthy aging. It is engaged in research on nicotinamide adenine dinucleotide (NAD+), levels of which decline with age. The company is the innovator behind NAD+ precursor nicotinamide riboside (NR), commercialized as the flagship ingredient Niagen. The company has three reportable segments namely Consumer Products, Ingredients segment, and Analytical Reference Standards and Services. The majority of the revenue is earned from the Consumer Products segment.